Why Hemab Therapeutics Holdings, Inc.’s (COAG) Stock Is Up 6.25%
As of Friday, November 06, Hemab Therapeutics Holdings, Inc.’s COAG share price has surged by 6.25%, which has investors questioning if this is right time to sell.Michael Rose
Stock Evaluator: Hemab Therapeutics Holdings, Inc. (COAG)
Hemab Therapeutics Holdings, Inc. COAG
$49.02
3.45
7.57%
November 6, 2026 4:00:00 PM
EST
Volume: 427,949
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
Commentary & Analysis
Why Hemab Therapeutics Holdings, Inc.’s (COAG) Stock Is Up 5.32%
As of Tuesday, November 03, Hemab Therapeutics Holdings, Inc.’s COAG share price has surged by 5.32%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Hemab Therapeutics Holdings, Inc.’s (COAG) Stock Is Up 5.38%
As of Thursday, October 29, Hemab Therapeutics Holdings, Inc.’s COAG share price has surged by 5.38%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Hemab Therapeutics Holdings, Inc.’s (COAG) Stock Is Up 5.36%
As of Wednesday, October 21, Hemab Therapeutics Holdings, Inc.’s COAG share price has surged by 5.36%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Hemab Therapeutics Holdings, Inc.’s (COAG) Stock Is Down 5.20%
As of Friday, October 16, Hemab Therapeutics Holdings, Inc.’s COAG share price has dipped by 5.20%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | COAG | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,289.8 | $219.9 | 57% |
|
| Shares Out (Mil) | 30.1 | 54.1 | 37% |
|
| Institutional Ownership | 99.4% | 92.9% | 88% |
|
| Float (Mil) | 20.3 | 41.4 | 29% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 522 | 522 | 58% |
|
| Price Change (52-week) |
na | 44.7% | na |
|
| Growth | COAG | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | ($0.515) | ($3.109) | ($2.547) | |
| Month Ago EPS | ($0.510) | ($3.100) | ($2.538) | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | ($0.487) | ($3.063) | ($2.513) | |
| Year/Year Chg | (35.8%) | (95.4%) | (95.4%) | |
| Financials | COAG | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($83) | ($44) | 12% |
|
| EPS (TTM) | ($10.055) | ($1.500) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($77) | ($35) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $137 | $0 | 80% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 15% |
|
| Enterprise Value (Q1) (Mil) | $1,317 | $166 | 44% |
|
| Valuation | COAG | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.04 | 2.06 | 81% |
|
| P/E | na | 16.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | COAG | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (61.0%) | na |
|
| ROA | (35.6%) | (47.5%) | 15% |
|
| ROE | (36.6%) | (52.7%) | 18% |
|
| Liabilities to Assets | 2.9% | 29.6% | 1% |
|
| F-Score | 1 | 3 | na |
|
Hemab Therapeutics Holdings, Inc. did not pass any screens on 11/6/2026.
